From Multiple Sclerosis to a Broad Pipeline of Autoimmune Therapies

Lead Program: TG-MS01 (MS)

Redefining MS Treatment at the Root

Multiple Sclerosis (MS) is a chronic autoimmune disease affecting over 2.9 million people worldwide, leading to progressive disability and lifelong treatment dependence. Despite decades of progress, current therapies primarily suppress symptoms and rarely achieve lasting remission.

TangGene’s lead program, TG-MS01, takes a fundamentally different approach — retraining the immune system at its root to restore myelin-specific tolerance and enable durable remission. Supported by strong preclinical and translational data, TG-MS01 is advancing toward IND-enabling studies and first-in-human trials, establishing the foundation for TangGene’s broader pipeline of curative autoimmune therapies.

From Science to Cures

TangGene’s pipeline represents more than programs in development — it is a path from breakthrough science to real cures, beginning with multiple sclerosis and expanding into major autoimmune diseases. By advancing a first-in-class CD8⁺ Treg therapy, we are working to transform how autoimmunity is treated and deliver lasting hope to patients worldwide.